Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refractory disease. To better define its efficacy in thi...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Lacy, MQ, Hayman, SR, Gertz, MA, Short, KD, Dispenzieri, A, Kumar, S, Greipp, PR, Lust, JA, Russell, SJ, Dingli, D, Zeldenrust, S, Fonseca, R, Bergsagel, PL, Roy, V, Mikhael, JR, Stewart, AK, Laumann, K, Allred, JB, Mandrekar, SJ, Rajkumar, SV, Buadi, F
Формат: Artigo
Язык:Inglês
Опубликовано: 2010
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2978257/
https://ncbi.nlm.nih.gov/pubmed/20827286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2010.190
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы